Back to Market返回行情

EXOZ eXoZymes, Inc.

USHealthcare
$8.48-0.24%ClosedMarket Cap: $78.7M

As of 2026-07-02

Why EXOZ matters now

eXoZymes, Inc. (EXOZ) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.48 with -0.24% on the session and $78.7M in market capitalization; recent performance reads 1-month -17.58% and YTD -28.17%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.4M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.7%.

The latest indexable market news headline is "eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery" from Accesswire.

Additional event context on this page matters because recent insider activity includes Korman Tyler Paz filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

43.34

P/S

0.00

EV/EBITDA

-6.72

DCF Value

$0.14

FCF Yield

-10.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-220.6%

ROA

-240.7%

ROIC

-362.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-2.4M$-0.28
Q4 2025$0.00$-2.7M$-0.32
FY 2025$0.00$-9.2M$-1.09
Q3 2025$0.00$-2.3M$-0.27

Trading Activity

Insider Trades

Korman Tyler Pazofficer: Chief Scientific Officer
Sell2026-04-10
Korman Tyler Pazofficer: Chief Scientific Officer
Sell2026-04-10
Korman Tyler Pazofficer: Chief Scientific Officer
Sell2026-04-08
Nawaz Fouadofficer: Vice President- Finance
Sell2026-04-08
Opgenorth Paul Hideoofficer: Vice President, Development
Sell2026-04-08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.66

Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.